Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient ...

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GVHD) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The report offers a ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

Graft-versus-host disease (GVHD) is a major complication of bone marrow transplantation even among HLA-matched donors and recipients. It has been generally considered that the severity of GVHD is ...

A “game-changing” Australian blood cancer treatment triples patients chances of surviving, being cancer free and avoiding ...

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Saint-Louis, France and Dublin, Ireland - 3rd June 2025- Priothera Ltd., a late-stage biopharma company pioneering the ...